Search | Clinical Trials Finder

Conditions: HIV, Therapeutic Vaccine
Interventions: rVSV, IL-12 pDNA adjuvant, HIV-Mag pDNA, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Covid19
Interventions: sotrovimab, Placebo to Biologic; Biological · Other
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Anaheim, California • Glendale, California

Conditions: Coronavirus, Covid19
Interventions: bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4,044 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 207
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Enzalutamide, Rucaparib camsylate, Placebo, Leuprolide Acetate, Goserelin Acetate, Degarelix, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 414
States / cities: Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 298 more

Conditions: Obesity, Menopausal Syndrome
Interventions: Placebo injection, Depo Lupron/Aromatase inhibitor, Depo Lupron/placebo, placebo, Estrogen cream; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 62 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Norovirus Prevention
Interventions: Norovirus Bivalent VLP Vaccine, Placebo (Saline); Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 454 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Coral Gables, Florida + 6 more

Conditions: Marburg Virus Disease
Interventions: cAd3-Marburg Vaccine, Placebo; Biological
Lead sponsor: Albert B. Sabin Vaccine Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 7
States / cities: Huntsville, Alabama • Phoenix, Arizona • Melbourne, Florida + 4 more

Conditions: HIV Infections
Interventions: MVA-CMDR, Placebo; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Diabetic Retinopathy
Interventions: Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Malignant Melanoma
Interventions: Intismeran autogene, Pembrolizumab, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Springdale, Arkansas • San Francisco, California • Hackensack, New Jersey + 2 more

Conditions: Healthy Volunteers
Interventions: Purified Inactivated Zika Virus Vaccine (PIZV), Placebo; Biological · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 5
States / cities: Oakland Park, Florida • Meridian, Idaho • Wichita, Kansas + 2 more

Conditions: Rheumatoid Arthritis
Interventions: IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate; Biological · Drug · Dietary Supplement
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 18
States / cities: Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Influenza
Interventions: Inactivated influenza vaccine, Placebo; Biological · Other
Lead sponsor: Mark Prausnitz; Other
Eligibility: 18 Years to 49 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Diabetic Nephropathies, Peripheral Nervous System Diseases
Interventions: PDA-002, Placebo; Biological · Drug
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Garden Grove, California • Orange, California • Orlando, Florida + 4 more

Conditions: Healthy
Interventions: MVA-BN-Filo, Ad26. ZEBOV, Placebo; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Cytomegalovirus Infections
Interventions: AVX601, Placebo; Biological
Lead sponsor: AlphaVax, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections
Interventions: Quadrivalent HPV Vaccine, Placebo Vaccine for Male Participants Only, Placebo Vaccine for Female Participants Only; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 27 Years and older
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 22
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 14 more

Conditions: Musculoskeletal Pain
Interventions: Placebo, EB-001; Drug
Lead sponsor: Bonti, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Lyme Disease
Interventions: VLA15, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years and older
Enrollment: 1,712 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 19
States / cities: Bangor, Maine • Worcester, Massachusetts • Flemington, New Jersey + 13 more

Conditions: Chronic Plaque Psoriasis
Interventions: alefacept, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 16 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 10
States / cities: Irvine, California • Santa Monica, California • Omaha, Nebraska + 7 more

Conditions: Pneumonia, Acute Respiratory Disease
Interventions: 23-valent pneumococcal vaccine, Placebo; Biological
Lead sponsor: Naval Health Research Center; Federal
Eligibility: Not listed
Enrollment: 152,723 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2007
U.S. locations: 5
States / cities: San Diego, California • Great Lakes, Illinois • Fort Leonard Wood, Missouri + 2 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene, Placebo; Biological · Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2038
U.S. locations: 52
States / cities: Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 40 more

Conditions: Healthy
Interventions: Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 329 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Search by objective public record fields.

Therapeutic Vaccine for HIV

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

ACTIV-2: A Study for Outpatients With COVID-19

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

Regulation of Cortisol Metabolism and Fat Patterning

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

Study of Evobrutinib in Participants With RMS

Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle

A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)

Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women

Study to Evaluate EB-001 in Reducing Musculoskeletal Pain

A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate

Effectiveness of the Pneumococcal Polysaccharide Vaccine in Military Recruits

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants